Published in Cancer Cell on November 01, 2005
NF-kappaB and cancer-identifying targets and mechanisms. Curr Opin Genet Dev (2008) 4.61
Drug development from marine natural products. Nat Rev Drug Discov (2008) 4.08
Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood (2007) 3.67
Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov (2010) 2.90
Proteasome inhibitors in multiple myeloma: 10 years later. Blood (2012) 2.77
A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med (2009) 2.62
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood (2010) 2.33
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol (2012) 2.26
Proteasome inhibitors activate autophagy as a cytoprotective response in human prostate cancer cells. Oncogene (2009) 2.13
Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood (2007) 1.89
NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells. Blood (2007) 1.86
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res (2011) 1.85
Discovery and characterization of a marine bacterial SAM-dependent chlorinase. Nat Chem Biol (2007) 1.85
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell (2012) 1.79
Discovery and development of the anticancer agent salinosporamide A (NPI-0052). Bioorg Med Chem (2008) 1.77
Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell (2009) 1.73
A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell (2013) 1.69
Proteasome inhibitors in the treatment of multiple myeloma. Leukemia (2009) 1.68
Marine actinomycetes: a new source of compounds against the human malaria parasite. PLoS One (2008) 1.67
Biosynthesis of polyketide synthase extender units. Nat Prod Rep (2009) 1.66
Role of proteasomes in disease. BMC Biochem (2007) 1.65
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood (2006) 1.56
The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem (2009) 1.55
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. Endocr Relat Cancer (2014) 1.52
E3 ubiquitin ligases as cancer targets and biomarkers. Neoplasia (2006) 1.49
Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. Chem Biol (2009) 1.47
The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol (2012) 1.46
Deubiquitinating enzymes as novel anticancer targets. Future Oncol (2007) 1.43
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood (2009) 1.41
A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood (2013) 1.38
Proteasome inhibitors in cancer therapy. J Cell Commun Signal (2011) 1.38
The 26S proteasome complex: an attractive target for cancer therapy. Biochim Biophys Acta (2011) 1.36
Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials. Curr Cancer Drug Targets (2011) 1.33
Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol (2013) 1.30
The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia (2009) 1.30
A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood (2010) 1.25
A novel proteasome inhibitor NPI-0052 as an anticancer therapy. Br J Cancer (2006) 1.25
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood (2009) 1.25
Targeting the ubiquitin-proteasome system for cancer therapy. Cancer Sci (2008) 1.24
Advances in the understanding of mechanisms and therapeutic use of bortezomib. Discov Med (2011) 1.23
Clinical development of novel proteasome inhibitors for cancer treatment. Expert Opin Investig Drugs (2009) 1.22
Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics. Angew Chem Int Ed Engl (2010) 1.22
Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem (2007) 1.19
Characterization of a new series of non-covalent proteasome inhibitors with exquisite potency and selectivity for the 20S beta5-subunit. Biochem J (2010) 1.18
Advances in and applications of proteasome inhibitors. Curr Opin Chem Biol (2008) 1.17
Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood (2008) 1.16
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin Cancer Res (2008) 1.14
Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment. Clin Cancer Res (2009) 1.14
Inhibition of Yin Yang 1-dependent repressor activity of DR5 transcription and expression by the novel proteasome inhibitor NPI-0052 contributes to its TRAIL-enhanced apoptosis in cancer cells. J Immunol (2008) 1.13
Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest (2014) 1.13
Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. Chem Biol (2011) 1.13
Caspase-8 dependent histone acetylation by a novel proteasome inhibitor, NPI-0052: a mechanism for synergy in leukemia cells. Blood (2009) 1.12
PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol (2010) 1.11
From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol (2007) 1.10
The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr Protein Pept Sci (2010) 1.08
Drug discovery from natural products. J Ind Microbiol Biotechnol (2006) 1.07
DangER: protein ovERload. Targeting protein degradation to treat myeloma. Haematologica (2012) 1.06
Targeting the UPS as therapy in multiple myeloma. BMC Biochem (2008) 1.05
Molecular mechanisms of acquired proteasome inhibitor resistance. J Med Chem (2012) 1.05
From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des (2013) 1.04
Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol (2011) 1.03
Discovery of a novel proteasome inhibitor selective for cancer cells over non-transformed cells. Cell Cycle (2009) 1.03
Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One (2009) 1.02
Control of HIF-1alpha expression by eIF2 alpha phosphorylation-mediated translational repression. Cancer Res (2009) 1.02
Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity and NF-kappaB with antimyeloma activity in vitro and in vivo. Blood (2008) 1.00
Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma (2009) 1.00
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol (2009) 1.00
Co-cultivation--a powerful emerging tool for enhancing the chemical diversity of microorganisms. Mar Drugs (2014) 0.99
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Invest New Drugs (2011) 0.97
Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs (2009) 0.96
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des (2013) 0.95
A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma. Invest New Drugs (2010) 0.95
Nature of pharmacophore influences active site specificity of proteasome inhibitors. J Biol Chem (2010) 0.94
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood (2011) 0.94
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood (2013) 0.93
Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites. J Med Chem (2013) 0.92
Inhibitors of the immunoproteasome: current status and future directions. Curr Pharm Des (2013) 0.92
New molecular targets in mantle cell lymphoma. Semin Cancer Biol (2011) 0.92
Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma. J Cell Mol Med (2014) 0.92
Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonism. J Inflamm (Lond) (2014) 0.92
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One (2013) 0.91
Actinomycetes from Red Sea sponges: sources for chemical and phylogenetic diversity. Mar Drugs (2014) 0.90
Proteasome inhibition and combination therapy for non-Hodgkin's lymphoma: from bench to bedside. Oncologist (2012) 0.90
In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res (2013) 0.89
Promising therapies in multiple myeloma. Blood (2015) 0.89
Marine-derived angiogenesis inhibitors for cancer therapy. Mar Drugs (2013) 0.89
Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors. Haematologica (2013) 0.89
The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J Biol Chem (2013) 0.89
Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr Oncol Rep (2008) 0.88
Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. Transl Oncol (2010) 0.88
Molecular targeted approaches in mantle cell lymphoma. Semin Hematol (2011) 0.88
The 26S proteasome is a multifaceted target for anti-cancer therapies. Oncotarget (2015) 0.88
Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation. Mol Cancer Res (2008) 0.87
New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J (2016) 0.87
Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol (2010) 0.87
Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am (2007) 0.86
A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag (2008) 0.86
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Whole-genome shotgun assembly and analysis of the genome of Fugu rubripes. Science (2002) 20.59
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
The draft genome of Ciona intestinalis: insights into chordate and vertebrate origins. Science (2002) 11.11
Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell (2006) 10.29
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Use of simulated data sets to evaluate the fidelity of metagenomic processing methods. Nat Methods (2007) 7.73
Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature (2003) 6.78
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing. Proc Natl Acad Sci U S A (2007) 6.14
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Genome sequencing and analysis of the biomass-degrading fungus Trichoderma reesei (syn. Hypocrea jecorina). Nat Biotechnol (2008) 5.38
Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest (2007) 5.02
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
A recurrent mutation in PALB2 in Finnish cancer families. Nature (2007) 4.64
Multiple myeloma. Lancet (2009) 4.60
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell (2007) 4.55
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Patterns and implications of gene gain and loss in the evolution of Prochlorococcus. PLoS Genet (2007) 4.25
Hematotoxicity in workers exposed to low levels of benzene. Science (2004) 4.19
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Control of mitochondrial apoptosis by the Bcl-2 family. J Cell Sci (2009) 3.54
Prednisolone or pentoxifylline for alcoholic hepatitis. N Engl J Med (2015) 3.47
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol (2002) 3.43
Legumes symbioses: absence of Nod genes in photosynthetic bradyrhizobia. Science (2007) 3.42
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Neuronal correlates of theory of mind and empathy: a functional magnetic resonance imaging study in a nonverbal task. Neuroimage (2005) 3.38
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Pathogenomic sequence analysis of Bacillus cereus and Bacillus thuringiensis isolates closely related to Bacillus anthracis. J Bacteriol (2006) 3.23
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12
Burkholderia xenovorans LB400 harbors a multi-replicon, 9.73-Mbp genome shaped for versatility. Proc Natl Acad Sci U S A (2006) 3.07
Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood (2011) 3.07
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood (2006) 3.04
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood (2002) 3.01
Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res (2002) 2.83
Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood (2007) 2.76
Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell (2005) 2.76
Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J Biol Chem (2004) 2.75
Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med (2006) 2.72